Bioengineered System for High Throughput Screening of Kv1 Ion Channel Blockers.

George V Sharonov, Oksana V Nekrasova, Ksenia S Kudryashova, Mikhail P Kirpichnikov, Alexey V Feofanov

Open access · goldAbstract read

In one paragraph

Article in Bioengineering (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.2field-weighted citation impact, top 50% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

Drug-Targeted Genomes: Mutability of Ion Channels and GPCRs.Biomedicines · 2022
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

George V SharonovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, 16/10 Miklukho-Maklaya, 117997 Moscow, Russia.ORCID 0000-0001-8610-5054

Oksana V NekrasovaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, 16/10 Miklukho-Maklaya, 117997 Moscow, Russia.ORCID 0000-0002-7216-1618

Ksenia S KudryashovaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, 16/10 Miklukho-Maklaya, 117997 Moscow, Russia.

Mikhail P KirpichnikovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, 16/10 Miklukho-Maklaya, 117997 Moscow, Russia.

Alexey V FeofanovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, 16/10 Miklukho-Maklaya, 117997 Moscow, Russia.ORCID 0000-0002-1596-9506

Lomonosov Moscow State University · RUInstitute of Bioorganic Chemistry · RUPrivolzhsky Research Medical University · RU

Funding

Ministry of Science and Higher Education of the Russian Federation Theme No. 0101-2019-0015

6 · The paper itself

Abstract

Screening drug candidates for their affinity and selectivity for a certain binding site is a crucial step in developing targeted therapy. Here, we created a screening assay for receptor binding that can be easily scaled up and automated for the high throughput screening of Kv channel blockers. It is based on the expression of the KcsA-Kv1 hybrid channel tagged with a fluorescent protein in the

Indexed as

agitoxinchannel blockerscharybdotoxinhigh throughput screeningkaliotoxinpotassium channelspheroplasts

Identifiers

PMID34821753

DOI10.3390/bioengineering8110187

PMCPMC8614864

OpenAlexW3211398737

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.